Acceleron Pharma (Acceleron Pharma) Debt-to-Equity : 0.03 (As of Sep. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Debt-to-Equity?

Acceleron Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $8.2 Mil. Acceleron Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $12.0 Mil. Acceleron Pharma's Total Stockholders Equity for the quarter that ended in Sep. 2021 was $718.2 Mil. Acceleron Pharma's debt to equity for the quarter that ended in Sep. 2021 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Acceleron Pharma's Debt-to-Equity or its related term are showing as below:

XLRN' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.87 Med: 0.06 Max: 0.68
Current: 0.03

During the past 10 years, the highest Debt-to-Equity Ratio of Acceleron Pharma was 0.68. The lowest was -3.87. And the median was 0.06.

XLRN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs XLRN: 0.03

Acceleron Pharma Debt-to-Equity Historical Data

The historical data trend for Acceleron Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma Debt-to-Equity Chart

Acceleron Pharma Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.03

Acceleron Pharma Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.03	0.03	0.03	0.03

Competitive Comparison of Acceleron Pharma's Debt-to-Equity

For the Biotechnology subindustry, Acceleron Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acceleron Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acceleron Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Acceleron Pharma's Debt-to-Equity falls into.

Acceleron Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Acceleron Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.01	+	17.067)	/	855.107
	=	0.03

Acceleron Pharma's Debt to Equity Ratio for the quarter that ended in Sep. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.163	+	11.951)	/	718.153
	=	0.03

Acceleron Pharma (NAS:XLRN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Acceleron Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acceleron Pharma (Acceleron Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

128 Sidney Street, Cambridge, MA, USA, 02139

Website

http://www.acceleronpharma.com

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Executives

Sujay Kango	officer: EVP, Chief Commercial Officer	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin	officer: SVP, CFO and Treasurer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness	officer: SVP, General Counsel and Sec.	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable	director, officer: CEO and President	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney	director	IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co	10 percent owner	430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George	director	CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik	director	C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139